Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
J Immunol. 2012 Oct 1;189(7):3397-403. doi: 10.4049/jimmunol.1201540. Epub 2012 Aug 22.
CD8(+) T cells have the potential to attack and eradicate cancer cells. The efficacy of therapeutic vaccines against cancer, however, lacks defined immune correlates of tumor eradication after (therapeutic) vaccination based on features of Ag-specific T cell responses. In this study, we examined CD8(+) T cell responses elicited by various peptide and TLR agonist-based vaccine formulations in nontumor settings and show that the formation of CD62L(-)KLRG1(+) effector-memory CD8(+) T cells producing the effector cytokines IFN-γ and TNF predicts the degree of therapeutic efficacy of these vaccines against established s.c. tumors. Thus, characteristics of vaccine-induced CD8(+) T cell responses instill a predictive determinant for the efficacy of vaccines during tumor therapy.
CD8(+) T 细胞具有攻击和消灭癌细胞的潜力。然而，基于 Ag 特异性 T 细胞反应的特征，治疗性疫苗对癌症的疗效缺乏明确的肿瘤消除的免疫相关性。在这项研究中，我们在非肿瘤环境中检查了各种肽和 TLR 激动剂基疫苗制剂引发的 CD8(+) T 细胞反应，并表明形成 CD62L(-)KLRG1(+)效应记忆 CD8(+) T 细胞，产生效应细胞因子 IFN-γ 和 TNF，可预测这些疫苗对已建立的皮下肿瘤的治疗效果。因此，疫苗诱导的 CD8(+) T 细胞反应的特征为肿瘤治疗期间疫苗的疗效提供了一个预测性决定因素。
